






-continued



-continued

9b



or a pharmaceutically acceptable salt thereof.

**14.** The compound of claim 1, wherein the compound is peripherally-restricted.

**15.** A pharmaceutical composition comprising a compound of claim 1, and a pharmaceutically acceptable excipient.

**16.** A method of reducing tactile dysfunction in a human subject diagnosed with Autism Spectrum Disorder (ASD), Rett syndrome (RTT), Phelan McDermid syndrome (PMS), or Fragile X syndrome, comprising administering to the subject the compound of claim 1 in an amount and for a duration sufficient to reduce the tactile dysfunction.

**17.** A method of reducing anxiety or social impairment in a human subject diagnosed with ASD, RTT, PMS, or Fragile X syndrome, comprising administering to the subject the compound of claim 1 in an amount and for a duration sufficient to reduce the anxiety or social impairment.

**18.** A method of treating touch over-reactivity and/or pain and/or mechanical allodynia in a human subject in need thereof, comprising administering to the subject a compound of claim 1 in an amount and for a duration sufficient to reduce the touch over-reactivity and/or pain and/or mechanical allodynia.

**19.** The method of claim 18, wherein the touch over-reactivity and/or pain is associated with a disease states selected from Sensory Processing Disorder (SPD) and fibromyalgia.

**20.** The method of claim 18, wherein the mechanical allodynia is associated with nerve injury, shingles, diabetic neuropathy, chemotherapy-induced neuropathy, or a neuropathic pain state.

**21.** The method of claim 16, wherein the subject is a child.

**22.** A kit comprising a compound of claim 1, and instructions for use.

\* \* \* \* \*